(Q35146077)

English

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Jianying Dong

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Arlene Sereno

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Dikran Aivazian

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Emma Langley

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Brian R Miller

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

William B Snyder

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Eric Chan

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Matt Cantele

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ronald Morena

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ingrid B J K Joseph

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Antonio Boccia

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Cyrus Virata

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

James Gamez

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Grace Yco

14

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michael Favis

15

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Xiufeng Wu

16

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Christilyn P Graff

17

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Qin Wang

18

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ellen Rohde

19

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Rachel Rennard

20

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Lisa Berquist

21

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Flora Huang

22

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ying Zhang

23

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sharon X Gao

24

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Steffan N Ho

25

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Stephen J Demarest

26

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Mitchell E Reff

27

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kandasamy Hariharan

28

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Scott M Glaser

29

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

1 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Monoclonal Antibodies

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

273-288

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Bispecific antibodies for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Cancer therapy with bispecific antibodies: Clinical experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Stability engineering of scFvs for the development of bispecific and multivalent antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Gefitinib for the treatment of non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Cetuximab: from bench to bedside.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Integration of panitumumab into the treatment of colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Affinity maturation by phage display

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

ErbB receptors and signaling pathways in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

EGFR-targeted therapies in lung cancer: predictors of response and toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Insulin and insulin-like growth factor signalling in neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Antibody therapeutics, antibody engineering, and the merits of protein stability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

The EGF receptor interacts with the type 1 IGF receptor and regulates its stability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Structural alterations of the epidermal growth factor receptor gene in human gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

28 July 2018

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

The insulin-like growth factor-I receptor as an oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

The IGF‐1 receptor in cancer biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3149708

27 September 2018

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.3.15188

21 January 2018

Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.3.15188

21 January 2018

Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.3.15188

21 January 2018

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.3.15188

21 January 2018

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

1 reference

https://pubmed.ncbi.nlm.nih.gov/21393993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21393993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin

1 reference

https://pubmed.ncbi.nlm.nih.gov/21393993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/21393993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/MABS.3.3.15188

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35146077&oldid=1527221840"